An arsenal of highly diversified compounds coming from a variety of sources enables Axxam to successfully address a wide variety of target types. For this reason, as part of our commitment to help our customers to rapidly identify promising hits, we offer high-throughput screening of both natural and synthetic compound collections.

Natural Compound Collection

An extensive collection of more than 500,000 different natural compound samples is available to Axxam from our partner InterMed Discovery GmbH. It is the largest screenable collection of pure Natural Product compounds and extracts available worldwide. Biological sources comprise over 40,000 microbial strains and several thousand other sources including plant material, marine microorganisms, and fruit bodies.

Please, contact us to request more information on the Natural Compound Collection available at Axxam.

Synthetic Compound Collection (AXX^DIV)

We have carefully assembled our own corporate synthetic compound screening collection (AXX^DIV). We use our library to screen your target and assay format of interest on Axxam’s automated screening stations.

AXX^DIV, assembled from leading commercial suppliers, is currently composed of 134,000 unique compounds carefully selected by our medicinal and computational chemists for lead-like and drug-like characteristics, as well as chemical diversity.

Please, contact us to request more information on our Synthetic Compound Collection (AXX^DIV).

Learn More [...]

For the creation and assembly of AXX^DIV, millions of commercially available compounds were filtered to select a set of compounds that serve as an excellent starting point for the identification of small molecule hits from a wide variety of target types. Particular attention was given to the choice of structurally diverse compounds, to represent a large chemical space. We also selected compounds with predicted favorable physicochemical and pharmacokinetic (ADMET) characteristics, to minimize the number of compounds in the library with undesirable properties and produce hits with a high chance of progressing into suitable leads for optimization.

More than 80% of our compound collection has zero violations of the Lipinski 'Rule of 5' for oral drug-like properties, and more than 70% has zero violations of the Oprea criteria for lead-like properties.

Using AXX^DIV means:

• Exposing your target of choice to more than 130,000 carefully selected small molecules
• Taking advantage of Axxam’s expertise in high throughput screening to identify meaningful Hits
• Obtaining the structures for all of your selected Hits
• Availability of compounds from commercial suppliers
• Consistent automation
• Miniaturization up to 1536-MTP format